Drugs that affect platelet function

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 865-883

  Scharf, Rüdiger E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

antibiotics; cardiovascular and lipid lowering drugs; drug interactions; nonsteroidal anti inflammatory drugs (NSAIDs); psychotropic agents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BETA LACTAM ANTIBIOTIC; CARDIOVASCULAR AGENT; CEPHALOSPORIN; CILOSTAZOL; CLOPIDOGREL; DICLOFENAC; DIPYRIDAMOLE; EPTIFIBATIDE; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIROXICAM; PRASUGREL; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG;

ABDOMINAL PAIN; ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BRADYCARDIA; CANCER CHEMOTHERAPY; CHINESE MEDICINE; CLOVE; CREATININE BLOOD LEVEL; CUMIN; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENTERIC COATED TABLET; FLUSHING; FOOD INTAKE; FUNGUS; GARLIC; GASTROINTESTINAL TOXICITY; GINGER; HEADACHE; HEART PALPITATION; HEARTBURN; HEMATOLOGICAL PARAMETERS; HEMOPHILIA; HEMOSTASIS; HUMAN; HYPOTENSION; INDIGESTION; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; ONION; PANCYTOPENIA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RASH; SIDE EFFECT; SPICE; STOMACH ULCER; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; URIC ACID BLOOD LEVEL; VITAMIN INTAKE; VOMITING;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; PHARMACEUTICAL PREPARATIONS; PLATELET AGGREGATION INHIBITORS;

EID: 84868541229     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328881     Document Type: Article

References (148)

1. Fuster V., Badimon L., Badimon J. J., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes [first of two parts]. N Engl J Med: 1992; 326 4 242 250
2. Ruggeri Z. M. Platelet interactions with vessel wall components during thrombogenesis. Blood Cells Mol Dis: 2006; 36 2 145 147
3. Ruggeri Z. M., Mendolicchio G. L. Adhesion mechanisms in platelet function. Circ Res: 2007; 100 12 1673 1685 (Pubitemid 46987859)
4. Iannacone M., Sitia G., Isogawa M., et al. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A: 2008; 105 2 629 634 (Pubitemid 351171759)
5. Wagner D. D., Burger P. C. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol: 2003; 23 12 2131 2137 (Pubitemid 37532311)
6. Boucharaba A., Serre C. M., Grès S., et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest: 2004; 114 12 1714 1725 (Pubitemid 40385527)
7. Gupta G. P., Massagué J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest: 2004; 114 12 1691 1693 (Pubitemid 40385522)
8. Semple J. W., Italiano J. E. Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol: 2011; 11 4 264 274
9. Ruggeri Z. M. Platelet adhesion under flow. Microcirculation: 2009; 16 1 58 83
10. Aguilar M., Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev: 2005; 4 CD001925
11. Antithrombotic Trialists'(ATT) Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ: 2002; 324 7329 71 86
12. Antithrombotic Trialists' (ATT) Collaboration Baigent C., Blackwell L., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet: 2009; 373 9678 1849 1860
13. Scharf R. E. Management of bleeding in patients using antithrombotic agents: prediction, prevention, protection and problem-oriented intervention. Hamostaseologie: 2009; 29 4 388 398
14. Eikelboom J. W., Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost: 2007; 5 01 255 263
15. May A. E., Geisler T., Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost: 2008; 99 3 487 493 (Pubitemid 351559482)
16. Scharf R. E. Acquired platelet function defects: an underestimated but frequent cause of bleeding complications in clinical practice. In: Scharf R. E., ed. Progress and Challenges in Transfusion Medicine, Hemostasis, and Hemotherapy. Freiburg, Germany Karger: 2008; 296 316
17. Shattil S., Bennett J. Acquired qualitative platelet disorders due to diseases, drugs, and foods. In: Beutler E., Lichtman M. A., Coller B. S., Kipps T. H., eds. Williams Hematology. 5th ed. New York, NY McGraw-Hill: 1995; 1386 1400
18. Michelson A. D. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov: 2010; 9 2 154 169
19. Catella-Lawson F., Reilly M. P., Kapoor S. C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med: 2001; 345 25 1809 1817
20. Patrono C., Baigent C., Hirsh J., Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 06 199S 233S (Pubitemid 351894914)
21. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med: 1994; 330 18 1287 1294 (Pubitemid 24129964)
22. Seidel H., Rahman M. M., Scharf R. E. Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie: 2011; 31 1 41 51
23. Santilli F., Rocca B., De Cristofaro R., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistanceo" J Am Coll Cardiol: 2009; 53 8 667 677
24. Patrono C., Andreotti F., Arnesen H., et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J: 2011; 32 23 2922 2932
25. Scharf R. E., Rahman M. M., Seidel H. The impact and management of acquired platelet dysfunction. Hamostaseologie: 2011; 31 1 28 40
26. Ferri A., Calza R., Pellegrini A., Cattani L. Two distinct mechanisms of inhibition of platelets aggregation by acetylsalicylic acid. Biochem Mol Biol Int: 1994; 32 6 1101 1107 (Pubitemid 24154326)
27. Turner N. A., Moake J. L., Kamat S. G., et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation: 1995; 91 5 1354 1362
28. Schrör K. Acetylsalicylsäure. 2nd ed. Frechen, Germany Dr. Schrör Verlag: 2011; 324 329
29. Weksler B. B. Regulation of prostaglandin synthesis in human vascular cells. Ann N Y Acad Sci: 1987; 509 142 148
30. Kaneshiro M. M., Mielke C. H. Jr, Kasper C. K., Rapaport S. I. Bleeding time after aspirin in disorders of intrinsic clotting. N Engl J Med: 1969; 281 19 1039 1042
31. Thomas P., Hepburn B., Kim H. C., Saidi P. Nonsteroidal anti-inflammatory drugs in the treatment of hemophilic arthropathy. Am J Hematol: 1982; 12 2 131 137 (Pubitemid 12152142)
32. Ragni M. V., Miller B. J., Whalen R., Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am J Hematol: 1992; 40 3 176 182
33. Favaloro E. J. Clinical application of the PFA-100. Curr Opin Hematol: 2002; 9 5 407 415
34. Favaloro E. J. Clinical utility of the PFA-100. Semin Thromb Hemost: 2008; 34 8 709 733
35. Patrono C., Rocca B. Aspirin, 110 years later. J Thromb Haemost: 2009; 7 01 258 261
36. George J. N., Shattil S. J. The clinical importance of acquired abnormalities of platelet function. N Engl J Med: 1991; 324 1 27 39
37. The Steering Committee of the Physicians' Health Study Research Group Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med: 1988; 318 4 262 264
38. The Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med: 1989; 321 3 129 135
39. Roderick P. J., Wilkes H. C., Meade T. W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol: 1993; 35 3 219 226 (Pubitemid 23074044)
40. Wolfe M. M., Lichtenstein D. R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med: 1999; 340 24 1888 1899 (Pubitemid 29272670)
41. Lee M., Cryer B., Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med: 1994; 120 3 184 189 (Pubitemid 24038801)
42. Wallace J. L., Ma L. Inflammatory mediators in gastrointestinal defense and injury. Exp Biol Med (Maywood): 2001; 226 11 1003 1015
43. Ma L., Elliott S. N., Cirino G., Buret A., Ignarro L. J., Wallace J. L. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A: 2001; 98 11 6470 6475 (Pubitemid 32488261)
44. Mannucci P. M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood: 1997; 90 7 2515 2521 (Pubitemid 27413458)
45. Mielke C. H. Jr. Comparative effects of aspirin and acetaminophen on hemostasis. Arch Intern Med: 1981; 141 3 spec no 305 310 (Pubitemid 11142890)
46. Kasper C. K., Rapaport S. I. Bleeding times and platelet aggregation after analgesics in hemophilia. Ann Intern Med: 1972; 77 2 189 193
47. Sattler F. R., Weitekamp M. R., Ballard J. O. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med: 1986; 105 6 924 931 (Pubitemid 17201773)
48. Burroughs S. F., Johnson G. J. Beta-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. Blood: 1990; 75 7 1473 1480 (Pubitemid 20114887)
49. Wisloff F., Godal H. C. Prolonged bleeding time with adequate platelet count in hospital patients. Scand J Haematol: 1981; 27 1 45 50 (Pubitemid 11011026)
50. Shattil S. J., Bennett J. S., McDonough M., Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest: 1980; 65 2 329 337 (Pubitemid 10159863)
51. Koscielny J., Ziemer S., Radtke H., et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost: 2004; 10 3 195 204 (Pubitemid 38982043)
52. Brown R. B., Klar J., Lemeshow S., Teres D., Pastides H., Sands M. Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med: 1986; 146 11 2159 2164 (Pubitemid 17189089)
53. Uchida K., Kakushi H., Shike T. Effect of latamoxef (moxalactam) and its related compounds on platelet aggregation in vitrostructure activity relationships. Thromb Res: 1987; 47 2 215 222 (Pubitemid 17095714)
54. Mihara S., Kakushi H., Shike T., et al. Effects of latamoxef on in vitro and ex vivo thromboxane A2 generation in human platelets. Thromb Res: 1988; 49 2 215 224 (Pubitemid 18085280)
55. Lipsky J. J. Antibiotic-associated hypoprothrombinaemia. J Antimicrob Chemother: 1988; 21 3 281 300
56. Ishikawa S., Manabe S., Wada O. Miconazole inhibition of platelet aggregation by inhibiting cyclooxygenase. Biochem Pharmacol: 1986; 35 11 1787 1792 (Pubitemid 16046200)
57. Gresele P., Momi S., Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol: 2011; 72 4 634 646
58. Rosen R. C., Kostis J. B. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol: 2003; 92 9A 9M 18M (Pubitemid 37386271)
59. Halcox J. P., Nour K. R., Zalos G., et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol: 2002; 40 7 1232 1240
60. Scharf R. E., Zotz R. B. Blood platelets and myocardial infarction: do hyperactive platelets really exist? Transfus Med Hemother: 2006; 33 2 189 199
61. Torfgård K. E., Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther: 1994; 8 5 701 717 (Pubitemid 24376750)
62. Dash D., Rao K. Effect of propranolol on platelet signal transduction. Biochem J: 1995; 309 pt 1 99 104
63. Larsson P., Olsson G., Hjemdahl P. Influence of beta-1-blockade on alterations in human platelet aggregability by mental stresss and adrenaline infusion (Abstract). Eur J Pharmacol: 1990; 183 332 (Pubitemid 20242905)
64. Knight C. J., Panesar M., Wilson D. J., et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation: 1997; 95 1 125 132 (Pubitemid 27029953)
65. Johnson G. J., Leis L. A., Francis G. S. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets. Circulation: 1986; 73 4 847 854 (Pubitemid 16081446)
66. Scharf R. E. Thrombozyten und Mikrozirkulationsstörungen. Stuttgart, Germany Schattauer: 1986
67. Hjemdahl P., Wallén N. H. Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J: 1997; 18 suppl A A36 A50 (Pubitemid 27107471)
68. Lawson D., Mehta J., Mehta P., Lipman B. C., Imperi G. A. Cumulative effects of quinidine and aspirin on bleeding time and platelet alpha 2-adrenoceptors: potential mechanism of bleeding diathesis in patients receiving this combination. J Lab Clin Med: 1986; 108 6 581 586 (Pubitemid 17186611)
69. Zahno A. Drug interactions and hepatotoxicity of clopidogrel. [PhD dissertation]. Faculty of Science, University of Basel, Switzerland; 2010
70. Zurbano M. J., Anguera I., Heras M., et al. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol: 1999; 19 7 1791 1795 (Pubitemid 29323841)
71. Bauriedel G., Skowasch D., Schneider M., Andrié R., Jabs A., Lüderitz B. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Am Heart J: 2003; 145 2 343 348 (Pubitemid 36207958)
72. Serebruany V. L., Pokov A. N., Malinin A. I., et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J: 2006; 151 1 92 99 (Pubitemid 41815336)
73. Shankar R. P., Bhargava V. K., Grover A., Majumdar S., Garg S. K. Involvement of nitric oxide in the antiaggregatory effect of enalapril. Methods Find Exp Clin Pharmacol: 2001; 23 5 255 257 (Pubitemid 33009603)
74. Chłopicki S., Koda M., Chabielska E., Buczko W., Gryglewski R. J. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol: 2000; 51 4 pt 1 715 722 (Pubitemid 32049523)
75. Sadowitz B., Seymour K., Costanza M. J., Gahtan V. Statin therapyPart II: Clinical considerations for cardiovascular disease. Vasc Endovascular Surg: 2010; 44 6 421 433
76. Sadowitz B., Maier K. G., Gahtan V. Basic science review: Statin therapyPart I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg: 2010; 44 4 241 251
77. Sposito A. C., Chapman M. J. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol: 2002; 22 10 1524 1534
78. Nissen S. E., Tuzcu E. M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med: 2005; 352 1 29 38 (Pubitemid 40075678)
79. Hansson G. K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med: 2005; 352 16 1685 1695
80. Labiós M., Martínez M., Gabriel F., Guiral V., Martínez E., Aznar J. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thromb Res: 2005; 115 4 263 270
81. Haramaki N., Ikeda H., Takenaka K., et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol: 2007; 27 6 1471 1477 (Pubitemid 46809440)
82. Osamah H., Mira R., Sorina S., Shlomo K., Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol: 1997; 44 1 77 83
83. Shattil S. J., Anaya-Galindo R., Bennett J., Colman R. W., Cooper R. A. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest: 1975; 55 3 636 643
84. Liao J. K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest: 2002; 110 3 285 288 (Pubitemid 34847957)
85. Ghittoni R., Patrussi L., Pirozzi K., et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J: 2005; 19 6 605 607 (Pubitemid 40471259)
86. Rikitake Y., Liao J. K. Rho GTPases, statins, and nitric oxide. Circ Res: 2005; 97 12 1232 1235
87. Carvalho A. C., Colman R. W., Lees R. S. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia. Circulation: 1974; 50 3 570 574
88. Ortega M. P., Sunkel C., Armijo M., Priego J. G. Effects of etofibrate on platelet function: in vitro studies in human plasma. Thromb Res: 1980; 19 3 409 416 (Pubitemid 10029571)
89. Heiden D., Mielke C. H. Jr, Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol: 1977; 36 3 427 436 (Pubitemid 8149941)
90. Warkentin T. E., Greinacher A., eds. Heparin-Induced Thrombocytopenia. 3rd ed. New York Marcel Dekker: 2004; 53 106, 335-370
91. Greinacher A., Kohlmann T., Strobel U., Sheppard J. A., Warkentin T. E. The temporal profile of the anti-PF4/heparin immune response. Blood: 2009; 113 20 4970 4976
92. Xiao Z., Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation: 1998; 97 3 251 256 (Pubitemid 28067310)
93. Horne M. K. III, Hutchison K. J. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol: 1998; 58 1 24 30 (Pubitemid 28213555)
94. Sobel M., Fish W. R., Toma N., et al. Heparin modulates integrin function in human platelets. J Vasc Surg: 2001; 33 3 587 594 (Pubitemid 32215610)
95. Gao C., Boylan B., Fang J., Wilcox D. A., Newman D. K., Newman P. J. Heparin promotes platelet responsiveness by potentiating αIIbβ3- mediated outside-in signaling. Blood: 2011; 117 18 4946 4952
96. Schafer A. I., Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest: 1985; 75 2 456 461 (Pubitemid 15143485)
97. Winters K. J., Santoro S. A., Miletich J. P., Eisenberg P. R. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation: 1991; 84 4 1552 1560
98. Penny W. F., Ware J. A. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood: 1992; 79 1 91 98
99. Green D., Ts'ao C. H., Cerullo L., Cohen I., Ruo T. I., Atkinson A. J. Jr. Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. J Lab Clin Med: 1985; 105 3 321 327 (Pubitemid 16239753)
100. Langdell R. D., Adelson E., Furth F. W., Crosby W. H. Dextran and prolonged bleeding time; results of a sixty-gram, one-liter infusion given to one hundred sixty-three normal human subjects. J Am Med Assoc: 1958; 166 4 346 351
101. Weiss H. J. The effect of clinical dextran on platelet aggregation, adhesion, and ADP release in man: in vivo and in vitro studies. J Lab Clin Med: 1967; 69 1 37 46
102. Aberg M., Hedner U., Bergentz S. E. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg: 1979; 189 2 243 247 (Pubitemid 9127375)
103. Kline A., Hughes L. E., Campbell H., Williams A., Zlosnick J., Leach K. G. Dextran 70 in prophylaxis of thromboembolic disease after surgery: a clinically oriented randomized double-blind trial. BMJ: 1975; 2 5963 109 112
104. Kelton J. G., Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol: 1980; 17 4 259 291
105. Mishler J. M. IV. Synthetic plasma volume expanderstheir pharmacology, safety and clinical efficacy. Clin Haematol: 1984; 13 1 75 92
106. Halperin D., Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci: 2007; 9 1 47 59 (Pubitemid 46607130)
107. Serebruany V. L. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med: 2006; 119 2 113 116 (Pubitemid 43151473)
108. Movig K. L., Janssen M. W., de Waal Malefijt J., Kabel P. J., Leufkens H. G., Egberts A. C. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med: 2003; 163 19 2354 2358 (Pubitemid 37310197)
109. Sewnath M. E., van Hillegersberg R., Koopman M. M., Levi M. M., Gouma D. J. [Increased perioperative blood loss during treatment with paroxetine]. Ned Tijdschr Geneeskd: 2002; 146 38 1800 1802
110. Turner M. S., May D. B., Arthur R. R., Xiong G. L. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med: 2007; 261 3 205 213
111. van Walraven C., Mamdani M. M., Wells P. S., Williams J. I. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ: 2001; 323 7314 655 658 (Pubitemid 32897004)
112. Yuan Y., Tsoi K., Hunt R. H. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med: 2006; 119 9 719 727 (Pubitemid 44291626)
113. Monto R. W., Talley R. W., Caldwell M. J., Levin W. C., Guest M. M. Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC 24559) therapy. Cancer Res: 1969; 29 3 697 704
114. Ahr D. J., Scialla S. J., Kimbali D. B. Jr. Acquired platelet dysfunction following mithramycin therapy. Cancer: 1978; 41 2 448 454 (Pubitemid 8289258)
115. Pogliani E. M., Fantasia R., Lambertenghi-Deliliers G., Cofrancesco E. Daunorubicin and platelet function. Thromb Haemost: 1981; 45 1 38 42 (Pubitemid 11155227)
116. McKenna R., Ahmad T., Ts'ao C. H., Frischer H. Glutathione reductase deficiency and platelet dysfunction induced by 1,3-bis(2-chloroethyl)-1- nitrosourea. J Lab Clin Med: 1983; 102 1 102 115 (Pubitemid 13071988)
117. Panella T. J., Peters W., White J. G., Hannun Y. A., Greenberg C. S. Platelets acquire a secretion defect after high-dose chemotherapy. Cancer: 1990; 65 8 1711 1716 (Pubitemid 20116639)
118. Mazharian A., Ghevaert C., Zhang L., Massberg S., Watson S. P. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood: 2011; 117 19 5198 5206
119. Oleksowicz L., Zuckerman D., Mrowiec Z., Puszkin E., Dutcher J. P. Effects of interleukin-2 administration on platelet function in cancer patients. Am J Hematol: 1994; 45 3 224 231 (Pubitemid 24053435)
120. Oleksowicz L., Puszkin E., Mrowiec Z., Isaacs R., Dutcher J. P. Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy. Cancer Invest: 1996; 14 4 307 316 (Pubitemid 26249167)
121. Grace A. A., Barradas M. A., Mikhailidis D. P., et al. Cyclosporine A enhances platelet aggregation. Kidney Int: 1987; 32 6 889 895 (Pubitemid 18015521)
122. Klein B. C., Bach D., Rehfeld I., et al. Influence of mycophenolic acid and FK-506 on human platelet activation in vitro. Kidney Blood Press Res: 2000; 23 2 119 124 (Pubitemid 30175631)
123. Dyerberg J., Bang H. O. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet: 1979; 2 8140 433 435 (Pubitemid 9250399)
124. Moncada S., Higgs E. A. Arachidonate metabolism in blood cells and the vessel wall. Clin Haematol: 1986; 15 2 273 292 (Pubitemid 16028873)
125. von Schacky C., Weber P. C. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest: 1985; 76 6 2446 2450 (Pubitemid 16155547)
126. Leaf A., Weber P. C. Cardiovascular effects of n-3 fatty acids. N Engl J Med: 1988; 318 9 549 557 (Pubitemid 18083576)
127. Reiter N., Jönsson B., Jansen E., Espersen K. [Vitamin E and excessive bleeding]. Ugeskr Laeger: 2005; 167 49 4664 4665
128. Stuart M. J., Oski F. A. Vitamin E and platelet function. Am J Pediatr Hematol Oncol: 1979; 1 1 77 82 (Pubitemid 11198766)
129. Norred C. L., Finlayson C. A. Hemorrhage after the preoperative use of complementary and alternative medicines. AANA J: 2000; 68 3 217 220 (Pubitemid 30421767)
130. Cowan D. H. Effect of alcoholism on hemostasis. Semin Hematol: 1980; 17 2 137 147 (Pubitemid 10088069)
131. Scharf R. E., Aul C. [Alcohol-induced disorders of the hematopoietic system]. Z Gastroenterol: 1988; 26 03 75 83
132. James M. J., Walsh J. A. Effects of aspirin and alcohol on platelet thromboxane synthesis and vascular prostacyclin synthesis. Thromb Res: 1985; 39 5 587 593 (Pubitemid 15228558)
133. Hammerschmidt D. E. Szechwan purpura. N Engl J Med: 1980; 302 21 1191 1193 (Pubitemid 10109976)
134. Dorso C. R., Levin R. I., Eldor A., Jaffe E. A., Weksler B. B. Chinese food and platelets. N Engl J Med: 1980; 303 13 756 757
135. Makheja A. N., Bailey J. M. Antiplatelet constituents of garlic and onion. Agents Actions: 1990; 29 3-4 360 363 (Pubitemid 20098466)
136. Srivastava K. C., Mustafa T. Spices: antiplatelet activity and prostanoid metabolism. Prostaglandins Leukot Essent Fatty Acids: 1989; 38 4 255 266 (Pubitemid 20077365)
137. Mackenzie I. S., Coughtrie M. W., MacDonald T. M., Wei L. Antiplatelet drug interactions. J Intern Med: 2010; 268 6 516 529
138. Kimmel S. E., Berlin J. A., Reilly M., et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol: 2004; 43 6 985 990 (Pubitemid 38352976)
139. Gupta E., Bansal D., Sotos J., Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci: 2010; 55 7 1964 1968
140. Kwok C. S., Loke Y. K. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther: 2010; 31 8 810 823
141. Bhatt D. L., Cryer B. L., Contant C. F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med: 2010; 363 20 1909 1917
142. Müller I., Besta F., Schulz C., Li Z., Massberg S., Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation: 2003; 108 18 2195 2197 (Pubitemid 37363034)
143. Mitsios J. V., Papathanasiou A. I., Rodis F. I., Elisaf M., Goudevenos J. A., Tselepis A. D. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation: 2004; 109 11 1335 1338 (Pubitemid 38387816)
144. Serebruany V. L., Midei M. G., Malinin A. I., et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med: 2004; 164 18 2051 2057 (Pubitemid 39390564)
145. Malmström R. E., Ostergren J., Jorgensen L., Hjemdahl P. CASTOR investigators Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med: 2009; 266 5 457 466
146. Ye Y., Perez-Polo J. R., Birnbaum Y. Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions. Ann N Y Acad Sci: 2010; 1207 76 82
147. Zotz R. B., Scharf R. E. [Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia]. Hamostaseologie: 2007; 27 4 251 262 (Pubitemid 47612020)
148. Mangano D. T., Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA: 2007; 297 5 471 479